Evotec’s cost-cutting drive has reached its pipeline. The biotech has axed around 30% of its asset portfolio and offloaded clinical program EVT 201 as part of a broader, ongoing attempt to correct its course.
Germany-based Evotec has a pipeline of assets that it co-owns with companies including Bristol Myers…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
LA JOLLA, Calif., March 12, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced […]
Melanie Squire Recognized for Pivotal Role in Mental Health Support for First Responders in Utah
SALT LAKE CITY, Nov. 29, 2023 /PRNewswire/ — Language is a powerful tool; few understand this better than Melanie Squire, a renowned trauma consultant and public speaker. Melanie has been a pillar of support following […]
Pure Healthcare tops the 2024 Utah 100, awarded by MountainWest Capital Network
Utah’s largest business networking organization shares its annual ranked list of the fastest growing companies in the state. SALT LAKE CITY, Oct. 2, 2024 /PRNewswire/ — MountainWest Capital Network (MWCN) recognized Pure Healthcare who took […]
